Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Adds to Pipeline of Personalized Healthcare Diagnostics

Published: Tuesday, January 08, 2013
Last Updated: Tuesday, January 08, 2013
Bookmark and Share
Includes investment in new companion diagnostic that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients.

QIAGEN N.V. has announced three separate agreements that add multiple biomarkers to QIAGEN's deep development pipeline of diagnostics for Personalized Healthcare applications to guide treatments with various medicines based on a patient's genomic information.

QIAGEN intends to develop new diagnostics to guide treatment decisions (including companion diagnostics paired with medicines) based on these biomarkers for use in therapeutic areas such as rheumatoid arthritis, lung cancer and colorectal cancer. Most of these assays will be designed to run on the QIAsymphony RGQ modular laboratory workflow automation system as well as QIAGEN's next-generation sequencing workflows currently in development. By guiding treatment decisions for specific therapies in individual patients, the use of these biomarkers as companion diagnostics can help improve patient outcomes and better utilize healthcare resources.

"These new agreements add further depth to our extensive development portfolio of biomarkers with potential to provide valuable diagnostic information as well as personalized guidance for treatment decisions. The opportunity to create a new, improved paradigm in the important and vast field of rheumatoid arthritis is very exciting, and the other agreements further deepen our pipeline in oncology," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "QIAGEN's global leadership in co-developing Personalized Healthcare solutions in partnership with pharmaceutical and biotechnology companies has become a key growth driver for our business. Our diagnostics are delivering molecular information to transform medical care for a wide range of diseases."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qiagen Completes Exiqon Tender Offer
Transaction will enhance leadership position in RNA solutions from Sample to Insight.
Friday, June 24, 2016
Qiagen Amends Terms to Exiqon Acquisition Offer Again
Acceptance rate lowered to 89.20% of share capital and voting rights to reflect possible effect of warrants.
Thursday, June 09, 2016
Qiagen Bids $100M to Acquire Exiqon
Transaction will expand leadership position in RNA technologies.
Thursday, March 31, 2016
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.
Tuesday, May 27, 2014
QIAGEN Receives FDA Clearance for QIAsymphony RGQ MDx
Clearance marks a milestone for one of the Company’s major global growth drivers.
Monday, May 05, 2014
QIAGEN Licences Biomarker for Blood Disorder from CeMM Vienna
Company plans to develop a molecular diagnostic test for the calreticulin mutations.
Thursday, April 10, 2014
QIAGEN Partners with Exosome Diagnostics
Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies.
Wednesday, July 24, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN’s KRAS Companion Diagnostic for Colorectal Cancer Adopted by Clarient
Clarient offers network of 2,000-plus pathologists testing with therascreen KRAS RGQ PCR Kit, the companion diagnostic for Erbitux® in metastatic colorectal cancer.
Wednesday, January 30, 2013
QIAGEN Submits Companion Diagnostic to FDA
Companion diagnostic intended to aid treatment decisions in non-small cell lung cancer.
Tuesday, January 22, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
Scientific News
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Quick, Early Test For Ebola Could Prevent Epidemics
Researchers from Princeton University are collaborating with U.S. government labs to develop a more rapid, accurate and inexpensive test for the Ebola virus with the aim of identifying infections before carriers become symptomatic and contagious.
From Super to Ultra-Resolution Microscopy
A new method pushes the frontier in imaging resolution, with the potential to distinguish individual features in single molecules.
Cancer Research UK joins forces with U.S. 'Cancer Moonshot'
Cancer Research UK and the US government’s National Cancer Institute have announced that two teams will work together to radically accelerate progress against cancer, in one of the first international collaborations inspired by US Vice President Joe Biden’s Cancer Moonshot.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Measuring the Abundance of Extremely Rare Mutations
Researchers from Rutgers University demonstrate the use of multiplex real-time PCR assays to measure the abundance of extremely rare mutations associated with cancer.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!